8 citations
,
October 2021 in “The international journal of risk and safety in medicine” This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.
This paper introduces a framework attributing Post-SSRI, Post-Finasteride, Post-Retinoid, and an unnamed sexual dysfunction syndrome to downregulated estrogen receptor activity, potentially guiding future treatments in sexual medicine.
20 citations
,
September 2019 in “Epidemiology and Psychiatric Sciences” This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.
